views
The increased prevalence of autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus (Lupus), juvenile rheumatoid arthritis, inflammatory bowel disease, Psoriatic arthritis, and others is driving the worldwide immunomodulators market. According to the National Institutes of Health, as many as 23.5 million Americans (almost 7% of the population) were diagnosed with an autoimmune disease in 2017, resulting in a larger patient pool and, as a result, a larger market.
The study's main components include an in-depth analysis of the immunomodulators market, as well as market size (in millions of dollars) and compound annual growth rate (in percent) forecasts for the years 2021-2028, using 2020 as the base year.
Read more @ https://cmilatestinsights.blogspot.com/2021/12/global-immunomodulators-market-global.html